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Abstract  
Nearly one-third of individuals with 22q11.2 deletion syndrome (22q11.2DS) develop 
a psychotic disorder during life, most of them by early adulthood. Importantly, a full-
blown psychotic episode is usually preceded by subthreshold symptoms. In the 
current study, 760 participants (ages 6–55 years) with a confirmed hemizygous 
22q11.2 microdeletion have been recruited through 10 medical sites worldwide, as 
part of an international research consortium. Of them, 692 were non-psychotic and 
with complete measurement data. Subthreshold psychotic symptoms were assessed 
using the Structured Interview for Prodromal Syndromes (SIPS). Nearly one-third of 
participants met criteria for positive subthreshold psychotic symptoms (32.8%), less 
than 1% qualified for acute positive subthreshold symptoms, and almost a quarter met 
criteria for negative/disorganized subthreshold symptoms (21.7%). Adolescents and 
young adults (13–25 years) showed the highest rates of subthreshold psychotic 
symptoms. Additionally, higher rates of anxiety disorders and attention 
deficit/hyperactivity disorder (ADHD) were found among the study participants with 
subthreshold psychotic symptoms compared to those without. Full-scale IQ, verbal 
IQ, and global functioning (GAF) scores were negatively associated with participants’ 
subthreshold psychotic symptoms. This study represents the most comprehensive 
analysis reported to date on subthreshold psychosis in 22q11.2DS. Novel findings 
include age-related changes in subthreshold psychotic symptoms and evidence that 
cognitive deficits are associated with subthreshold psychosis in this population. Future 
studies should longitudinally follow these symptoms to detect whether and how early 
identification and treatment of these manifestations can improve long-term outcomes 
in those that eventually develop a psychotic disorder. 
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Introduction 
22q11.2 deletion syndrome (22q11.2DS) is a genetic disorder that occurs in about 1 in 
4,000 live births.1 Psychiatric comorbidities are highly prevalent in 22q11.2DS, 
affecting three-quarters of all diagnosed individuals.2 Notable among these are 
Schizophrenia-spectrum disorders; about a third of 22q11.2DS individuals develop a 
psychotic disorder during life, most of them by early adulthood.3 Thus, a diagnosis of 
22q11.2DS constitutes a 30-fold increased risk of developing psychosis over the 
general population and a 10-fold elevated risk over other populations with 
neurodevelopmental disabilities.4 Therefore, 22q11.2DS is currently the strongest 
known risk factor for psychosis and a promising model for studying the etiology of 
schizophrenia and early signs of psychosis proneness.5,6 
 As in non-deleted individuals, psychotic symptoms develop gradually in those 
with 22q11.2DS, and psychosis is usually preceded by subthreshold symptomology.7,8 
Few studies have assessed subthreshold psychotic symptoms in 22q11.2DS reporting 
prevalence rates ranging from 20% to 56.5%.5,9–12 Small sample sizes, differences in 
participants' age, various definition of “prodromal symptoms” used (i.e., including 
positive symptoms, negative/disorganized symptoms, or both), and the assessment 
tool employed, may contribute to the variability in reported rates. 
These inconsistencies call for additional investigation into the incidence and 
characteristics of subthreshold psychotic symptoms in 22q11.2DS from early 
childhood through adulthood. An analysis that is based on a large cohort of 
participants undergoing comparable clinical assessments is likely to provide answers 
to some of the questions that arise due to the limitations in the literature.  
 Several well-validated diagnostic tools are applied for assessing subthreshold 
psychotic symptoms, including the Structured Interview for Prodromal Syndromes 
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(SIPS).13 Originally developed for the evaluation of subthreshold psychotic symptoms 
in the general population14, the SIPS has good psychometric properties13, and criteria 
for a clinical high-risk state have been shown to predict conversion to psychosis in 
non-deleted populations (~20% by 1-year and 33% by 3-years).15,16 The SIPS has 
been effectively administered to individuals with 22q11.2DS in several studies.5,9–12  
 Several factors may contribute to developing psychosis in individuals with 
22q11.2DS. Among these are longitudinal decline in verbal IQ (VIQ),17,18 lower 
baseline IQ,3,8,19 the presence of comorbid anxiety disorders,7,8,20 and lower global 
functioning.21,22 However, the comorbidity of these conditions with subthreshold 
psychotic symptoms has not been sufficiently explored. Moreover, assessment of this 
phenomenon in 22q11.2DS individuals of various ages is vital for elucidating the rate 
and nature of subthreshold psychotic symptoms across development in this 
population.    
 Accordingly, the aims of the current study are: 1. To determine the rates of 
positive and negative/disorganized subthreshold psychotic symptoms in the largest 
cohort of 22q11.2DS individuals published to date; 2. To investigate (cross-sectional) 
changes in the prevalence of different definitions of subthreshold symptoms across 
development - from early childhood throughout adulthood; 3. To determine whether 
higher rates of psychiatric comorbidities and lower intellectual and global functioning 
co-occur with subthreshold psychotic symptoms. 
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Methods 
Participants 
This study represents the collaborative efforts of researchers across 10 independent 
medical centers worldwide, 6 in the U.S., 3 in Europe, and 1 in Israel (table 1 lists the 
demographics and enrollment specifications for each site). The sites are part of the 
International 22q11.2 Deletion Syndrome Brain Behavior Consortium (IBBC). 
Participants had a 22q11.2 microdeletion confirmed by molecular testing, underwent a 
structured clinical assessment of psychiatric psychopathologies, and completed the 
SIPS interview for evaluating subthreshold psychotic symptoms. Of the 839 
individuals originally enrolled in the study, 79 were excluded due to missing data on 
the SIPS positive symptoms (>9%), resulting a total of 760 participants aged 6-55 
years (mean age, 17.1±6.8).  
Of the study sample (n=760), 56 participants (7.4%) were on antipsychotic 
medication, 118 participants (15.5%) were taking antidepressants, 26 participants 
(3.4%) were taking a mood-stabilizer, 34 participants (4.5%) were taking an 
anxiolytic medication and 104 participants (13.7%) were taking stimulants.  
Each site received approval from its local ethics committee (institutional 
review board; IRB), and each participant or his or her legal caregiver gave written 
informed consent prior to study entry.  
 
SIPS Administration and Scoring 
Participants were evaluated for the presence of subthreshold psychotic symptoms by a 
well-trained Bachelor’s, Master’s, Doctoral, or Post-doctoral/Resident-level 
interviewers skilled in using the SIPS Scale of Prodromal Symptoms (SOPS).13 
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Furthermore, all interviewers were routinely supervised by psychiatry and psychology 
faculty, knowledgeable in using the SIPS, at each of the participating sites.  
The SOPS is composed of 19 items, each representing a different possible 
subthreshold psychotic symptom, yielding four constructs: Positive, Negative, 
Disorganized and General symptoms.13 Each item is rated on a seven-point scale (0-
absent, 1-questionably present, 2-mild, 3-moderate, 4-moderately severe, 5-severe but 
not psychotic, 6-severe and psychotic/extreme).  
Some items of the SIPS are more entangled with non-psychotic comorbidities. 
For example, D3, “trouble with focus and attention”, overlaps significantly with 
ADHD, and N5, poor “ideational richness”, overlaps with reduced intellectual ability. 
In these cases, we considered that these symptoms nevertheless might represent 
subthreshold psychotic symptoms. Therefore, we rated these SIPS items based on 
their presence and without regard to other comorbidities. As such, dual scoring was 
given for the same symptom of inattention in the SIPS and in the ADHD section of 
the K-SADS. This is consistent with the original intention of the SIPS, that items be 
rated without regard to diagnostic etiology.23 
In the majority of cases, separate interviews were conducted with probands 
and their caregivers, usually mothers. The SIPS was administered separately from the 
child to all parents of children younger than 18 years of age, as well as for parents of 
adult participants when possible. Younger probands (aged 6–10 years) underwent 
clinical evaluations probing for subjective and characteristic symptoms (including 
delusional and bizarre ideas, suspiciousness, grandiosity, perceptual abnormalities, 
disorganized speech, social anhedonia, and avolition). Probands aged 11 years and 
older received the full SIPS. Whenever there were discrepancies in the provided 
information, each responder was asked for clarification. 
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Establishing Reliability in Assessing Subthreshold Psychotic Symptoms between Two 
Participating Sites: Philadelphia and Israel 
The Tel Aviv and Philadelphia sites are funded, as part of a binational 
prospective research project, to study psychosis risk in 22q11.2DS. Thus, the two 
centers conducted training sessions to ensure the consistency of SIPS administration 
and scoring methodology. The high inter-rater reliability achieved suggests that multi-
site studies that aim to reliably assess subthreshold psychotic symptoms in individuals 
with 22q11.2DS are feasible. This is especially important in the context of 
administering the SIPS – which was originally developed for use in the general 
population – to individuals with neurodevelopmental and neurogenetic conditions, 
such as 22q11.2DS. The low IQ (and, respectively, the poor ideational richness) that 
characterizes many 22q11.2DS individuals makes SIPS administration a challenging 
task that requires skilled personnel. The international 22q11.2 Deletion Syndrome 
consortium is a multi-center study geared towards characterization of a large cohort of 
existing data sets. The retrospective nature of the project therefore focused on data 
harmonization and reliability is currently pursued in several sites. The following 
paragraph details the efforts of two sites. 
The Israeli team was trained by the PI from the Philadelphia site (R.E.G) to 
administer the SIPS in the same manner that it is being conducted in the Philadelphia 
22q11.2DS study. Consequently, in both sites the SIPS interview was conducted 
separately for participants and caregivers. Whenever discrepancies emerged between 
the 22q11.2DS and collateral informants, a combined rating was given in a consensus 
meeting. Four cases from the Israeli cohort were independently evaluated and given 
SIPS scores by R.E.G. and the clinical psychologist from the Israeli site (Y.G.).  
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The between-site weighted kappa intra-class correlation coefficients (ICC) for 
the SIPS items presented for both centers in this study ranged between very good to 
excellent (besides the ICC for N5, "ideational richness"): P1, “unusual thought 
content/delusional ideas” (ICC = 0.99),  P2, “”suspiciousness/persecutory ideas” 
(0.98), P3, “grandiosity” (0.98), P4, “perceptual abnormalities/hallucinations” (1.00), 
P5, “disorganized communication” (0.98), N1, “social anhedonia” (0.95), N2, 
“avolition” (0.95), N3, “expression of emotion” (0.98), N4, “experience of emotions 
and self” (1.00), N5, “ideational richness” (0.00), N6, “occupational functioning” 
(1.00), D1, “odd behavior or appearance” (0.97), D2, “dysphoric mood” (1.00), D3, 
“trouble with focus and attention” (0.89), and D4, “personal hygiene” (0.95).  
 
Subthreshold Psychotic Symptoms Definitions 
The spectrum of subthreshold psychotic symptoms, consistent with the deleted and 
none-deleted literature, was defined in four categories.5,16,24 Positive subthreshold 
psychotic symptoms - having one or more positive symptoms rated 3-5; acute positive 
subthreshold psychotic symptoms - having at least one positive symptom rated 6 
without fulfilling criteria for a psychotic spectrum disorder; negative/disorganized 
subthreshold psychotic symptoms - having at least two negative/disorganized 
symptoms rated 3-6 (without the presence of positive subthreshold symptoms); 
positive and negative/disorganized subthreshold psychotic symptoms - having one or 
more positive symptoms rated 3-5 and at least two negative/disorganized symptoms 
rated 3-6.  
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Psychiatric Evaluation 
Probands and their caregivers were interviewed by trained psychiatrists or 
psychologists using the Schedule for Affective Disorders and Schizophrenia for 
School-Aged Children, Present and Lifetime (K-SADS-PL)25 in 8 centers, the 
Diagnostic Interview for Children and Adolescents (DICA)26 in one center (Geneva), 
and the Child and Adolescent Psychiatric Assessment (CAPA)27 in another center 
(Cardiff). Adult participants were interviewed using the Structured Clinical Interview 
for Axis I DSM-IV (SCID)28 in 9 centers and the PAS-ADD clinical interview for 
adults29 in one center (Cardiff).  
Psychiatric diagnoses were established, when appropriate, according to the 
fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-
IV).30 Nearly all of the participants underwent clinical evaluation for the presence of 
schizophrenia spectrum disorders (n=756; 64 fulfilled the criteria), anxiety disorders 
(n=757; 310 fulfilled the criteria), mood disorders (n=760; 133 fulfilled the criteria), 
attention deficit/hyperactivity disorders (ADHD; n=732; 257 fulfilled the criteria, 
oppositional defiant and conduct disorders (n=731; 26 fulfilled the criteria), and 
substance-related disorders (n=626; 15 fulfilled the criteria). Prevalence rates of 
psychotic disorders and other psychiatric comorbidities are detailed in table S1. 
Of the 760 participants with complete data on the SIPS positive items, 68 were 
excluded from the statistical analysis due to fulfillment of the criteria for 
schizophrenia spectrum disorders (n=64), or not completing clinical evaluation (n=4). 
Consequently, the final study cohort included 692 participants aged 6-55 years (mean 
age, 16.9±6.7). Of them, 350 participants were males (50.6%), 429 Caucasians (62%), 
235 Afro-Americans (34%), 10 of mixed ethnicity (1.4%), and 9 Hispanic (1.3%).   
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Intellectual Functioning  
Age-appropriate Wechsler intelligence scales were used for assessment of intellectual 
functioning, including the Wechsler Preschool and Primary Scale of Intelligence 
(WPPSI),31 the Wechsler Intelligence Scale for Children-Revised (WISC-R),32 the 
Wechsler Intelligence Scale for Children-Third Edition (WISC-III),33 the Wechsler 
Abbreviated Scale of Intelligence-Second Edition (WASI-II)34, and the Wechsler 
Adult Intelligence Scale-Third Edition (WAIS-III).35 A total of 521 participants 
(68.4%) completed the evaluation. The mean full-scale IQ (FSIQ) was 76.3±13.2 
points, and the mean VIQ (assessed in 507 participants) was 79.8±13.7 points. There 
were 187 individuals (35.9%) with a FSIQ≤70, consistent with intellectual disability. 
Age was not significantly associated with FSIQ score (Pearson r=0.03, p=0.45).  
 
Statistical Analysis 
Statistical analysis was conducted using SPSS Version 20.0. To compare the rates of 
subthreshold psychotic symptoms at different stages of development, the cohort was 
divided into 4 age groups: 6 to 12 years (children), 13 to 17 years (adolescents), 18 to 
25 years (young adults), and 26 years and above (older adults). The prevalence rates 
of positive subthreshold psychotic symptoms (i.e., having one or more positive 
symptoms rated 3-5) and the combined subgroup of symptoms (i.e., having one or 
more positive symptoms rated 3-5 and/or at least two negative/disorganized 
symptoms rated 3-6) were compared between the four different age groups using the 
χ2 test and with Fisher exact test when the χ2 test assumptions were not met. A 
significant difference between all four groups was followed by post-hoc contrast 
analysis comparing the group with the highest rates of subthreshold symptoms 
(Adolescents, aged 13 – 17 y) to all other groups. The False Discovery Rate (FDR) 
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method for adjustment of significance level was computed using SAS for Windows 
version 9.4.   
Univariate analysis of variance (ANOVA) was applied to examine differences 
in the scores of individual SIPS items between the age groups. Bonferroni post-hoc 
comparisons were conducted only for the items that reached statistical significance at 
the level of p<0.003 (0.05/15, with 15 representing the number of comparisons/ 
number of SIPS items).  
Next, independent t-tests were calculated to compare between (a) 22q11.2DS 
with positive subthreshold psychotic symptoms (i.e., having one or more positive 
symptoms rated 3-5) vs. those without positive subthreshold symptoms or acute 
positive subthreshold symptoms, and (b) 22q11.2DS with negative/disorganized 
subthreshold psychotic symptoms (i.e., having at least two negative/disorganized 
symptoms rated 3-6) vs. those without positive or negative/disorganized subthreshold 
symptoms. Analyses were corrected for multiple comparisons (p value lower than 
.0062 was regarded as significant). The positive and negative/disorganized 
subthreshold symptoms were chosen as each of them is a risk factor for the evolution 
of psychotic disorders in non-deleted and deleted individuals. Potential contribution of 
research sites to the variability in individual items between the age groups was 
controlled for by including site as covariate (See Table S3). 
 
Results 
Prevalence of Subthreshold Psychotic Symptoms  
Nearly one-third of participants met criteria for positive subthreshold psychotic 
symptoms (228/692; 32.8%), less than 1% qualified for acute positive subthreshold 
psychotic symptoms (6/692), and almost a quarter of participants met criteria for 
12 
 
negative/disorganized subthreshold psychotic symptoms where positive subthreshold 
psychotic symptoms were not present (140/641; 21.7%). Finally, one-fourth of 
participants (160/692; 25.6%) met criteria for both positive and negative/disorganized 
subthreshold psychotic symptoms.  
About 90% of the participants who rated 6 on at least one positive SIPS item 
were diagnosed with a psychotic disorder (48/54) compared to 6% of those who rated 
3-5 (15/242), χ2(1)=180.18, p<0.001, η2=.78. Participants with both positive and 
negative/disorganized symptoms were more likely to be diagnosed with psychotic 
disorder (7/167) compared to participants who met criteria for the negative/ 
disorganized definition solely (0/140), Fisher exact test=6.00, df=1, p<0.05.  
Notably, 66.3% of the participants did not meet criteria for either positive or 
acute positive subthreshold psychotic symptoms (459/692). Of this group, the 
majority (65.9%) did not meet criteria for the negative/disorganized definition either. 
The most prevalent subthreshold symptom was poor ideational richness, 
followed by trouble with focus and attention, avolition, and occupational functioning. 
The least prevalent symptoms were grandiosity and bizarre thinking. Individual item 
scores and subthreshold rates in the entire 22q11.2DS cohort are described in Table 2. 
 
Subthreshold Psychotic Symptoms from Early Childhood throughout Adulthood 
Significant differences between the age groups were found in the positive 
subthreshold psychotic symptoms subgroup and the combined (positive and negative/ 
disorganized) subthreshold psychotic symptoms subgroup. Post-hoc contrast analysis 
using FDR for adjustment of significance level revealed significantly higher rates of 
positive subthreshold symptoms in adolescents compared to children, FDR = 0.039, 
χ2(1)=6.07, p<0.02, η2=.12, and older adults, FDR = 0.047, χ2(1)=4.47, p<0.03, 
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η2=.12.  In the same vein, a post-hoc contrast analysis conducted for the combined 
subthreshold symptoms subgroup revealed higher rates in adolescence compared to 
children, FDR = 0.027, χ2(1)=9.30, p<0.003, η2=.18, and older adults, FDR = 0.013, 
χ2(1)=8.34, p<0.005, η2=.20. The acute positive symptoms subgroup has been 
diagnosed in a limited number of individuals, and it was present in children and 
adolescents but absent among adults (table 3).  
Age-related differences in mean scores of positive, negative, and disorganized 
symptoms emerged. Specifically, adolescents scored higher on items: P4, “perceptual 
abnormalities/ hallucinations”, F(3,686)=6.20, p<0.001, η2=.02,  N1, “social 
anhedonia”, F(3,616)=6.94, p<0.001, η2=.03, N3, “expression of emotion”, 
F(3,617)=17.00, p<0.001, η2=.07, N4, “experience of emotions and self”, 
F(3,597)=6.11, p<0.001, η2=.03, and, N5, poor “ideational richness”, F(3,617)=17.33, 
p<0.001, η2=.08, compared to all or most other age groups. Finally, children and 
adolescents scored significantly higher on item D3, “trouble with focus and attention”, 
F(3,620)=16.92, p<0.001, η2=.08, compared to the young adults and older adults 
groups (See figure 1 and table S2 for details). 
 
Psychiatric Comorbidities, Intellectual Functioning, and Global Functioning in 
Affected vs. Non-Affected Individuals 
The rates of anxiety disorders has been significantly higher in participants with 
positive subthreshold psychotic symptoms compared to those without (55.1% vs. 
35.1%, χ2(1)=25.54, p<0.001, η2=.19; table 4). In addition, intellectual functioning 
(FSIQ) and global functioning (GAF) scores were lower in subjects with positive 
subthreshold symptoms compared to those without (FSIQ, 74.4±12.0 vs. 78.2±13.3, 
t(467)=3.01, p=0.002; GAF, 57.4±12.1 vs. 69.4±46.6, t(664)=3.83, p<0.001) (table 4).  
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The rates of anxiety disorders and ADHD have been significantly higher in 
subjects with negative/disorganized subthreshold psychotic symptoms compared to 
those without (43.6% vs. 29.6%, χ2(1)=7.94, p=0.006, η2=.14, and 44.0% vs. 27.3%, 
χ2(1)=10.75, p=0.001, η2=.16, respectively; table 4). Intellectual functioning (FSIQ, 
VIQ) and global functioning (GAF) scores have been lower in subjects with 
negative/disorganized subthreshold symptoms compared to those without (FSIQ, 
75.8±12.3 vs. 80.7±12.8, t(268)=3.12, p=0.002; VIQ, 78.3±12.7 vs. 83.3±13.7, 
t(258)=1.77, p=0.004; GAF, 60.4±14.8 vs. 71.4±11.35, t(384)=8.13, p<0.001, 
respectively).  
 
Discussion 
This multi-site study represents the largest cohort and the most comprehensive 
analysis reported to date on subthreshold psychotic symptoms in individuals with 
22q11.2DS. The novel aspects of our study include an examination of the 
development of subthreshold psychotic symptoms by age groups, and evidence that 
cognitive deficits are associated with subthreshold psychosis in this population. 
Specifically, we show that the peak prevalence of positive subthreshold psychotic 
symptoms occurs during adolescence and young adulthood (ages 13 to 25 years), 
which is similar or slightly later than the peak occurrence of subthreshold syndrome 
reported in non-help-seeking typically developing individuals.36 Furthermore, our 
findings indicate that FSIQ scores are significantly lower in 22q11.2DS individuals 
with vs. without subthreshold psychotic symptoms. Of note, lower IQ has been 
associated with psychotic disorders2 and with the risk for developing psychotic 
disorders in 22q11.2DS.7  
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Psychiatric comorbidities in 22q11.2DS are common,2 and our study provides 
additional evidence that conditions of subthreshold psychosis are characterized by an 
extent of psychiatric symptomology, including anxiety and mood disorders and higher 
rates of ADHD,37 coupled with lower FSIQ scores. These comorbidities are similar to 
those reported in non-deleted individuals.38,39 Findings in non-deleted individuals 
show that psychiatric disorders tend to be less specific in early stages and more so 
with progression.39 Notably, the majority of non-deleted individuals with subthreshold 
psychotic symptoms do not develop schizophrenia spectrum disorders.40 Many 
patients with subthreshold psychotic symptoms progress to develop other psychiatric 
disorders such as anxiety and affective disorders.  
It is plausible that the subthreshold psychotic symptoms in 22q11.2DS are not 
pathognomonic since only a portion of the deleted individuals develop psychosis 
while many others will evolve to other psychiatric morbidities such as anxiety 
disorders and depression. An answer to this question will be provided by longitudinal 
studies that have only begun to examine the outcome of 22q11.2DS individuals with 
subthreshold psychotic symptoms.41 Besides the need to find the proportion of 
subthreshold 22q11.2DS individuals who will develop full-blown psychosis, it is also 
important to determine the proportion of the subthreshold 22q11.2DS individuals who 
will continue to cope with or will develop mood disorders, anxiety disorders and 
ADHD,37 as these disorders have been shown to negatively affect the quality of life 
and functioning of individuals with 22q11.2DS.42–44  
The collective prevalence rates of those with positive subthreshold symptoms 
(32.8%) and those with negative/disorganized subthreshold symptoms (21.7%) sum 
up to 54.5%, which is similar to the 54% who met criteria for “psychosis-proneness” 
in the research conducted by Tang et al., 2014.5 Similarly, the rates of 
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negative/disorganized subthreshold symptoms found in our cohort parallel those 
reported in several previous studies with 22q11.2DS individuals, suggesting that 
negative symptoms are common in this population.11,22 
 Negative symptoms are considered important predictors of the likelihood to 
convert to psychosis in non-22q11.2DS high-risk populations.11,45 For example, 
moderate and severe subthreshold negative symptoms were highly abundant in 
individuals at high risk for psychosis in the North American Prodrome Longitudinal 
Study (NAPLS), and the severity and persistence of these symptoms were positively 
associated with transition rates into a psychotic state at 6- and 12-months post-
baseline visits.45 Another study which assessed negative subthreshold psychotic 
symptoms in typically developing youths found significant associations with the 
participants' neurocognitive performance and functions that are central to the 
evolution of psychosis.46 Taken together, the accumulating evidence suggest that 
22q11.2DS individuals with subthreshold negative symptoms in our study are at 
higher risk of transitioning into full-blown psychotic disorders. 
Nevertheless, in 22q11.2DS literature, negative symptoms, most notably, 
ideational richness and trouble with focus and attention (i.e., ADHD), have been 
suggested as features of the general phenotype of the syndrome,47 regardless of the 
degree of the risk for psychosis. This indicates that negative symptoms may not yield 
the predictive power that positive symptoms may yield, particularly in adolescents 
who are more likely to endorse negative symptoms than children and, in some cases, 
adults.48 Accordingly, future studies should examine whether, and at what ages, the 
presence of negative subthreshold symptoms also predicts the emergence of psychosis 
in the 22q11.2DS population. Prospective multi-center studies are needed to adapt the 
SIPS to neurodevelopmental disorders with below-average IQ and excess psychiatric 
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comorbidities (including ADHD), as is the case with most individuals with 
22q11.2DS. 
A limitation of the current analysis might be related to the lack of establishing 
cross-site reliability of the SIPS. However, the Tel Aviv and Philadelphia sites 
conducted joint training sessions to ensure the consistency of SIPS administration and 
scoring methodology (as detailed in the Methods section). The inter-rater reliability 
scores achieved were excellent (besides N5, kappa scores≥0.89), indicating the 
feasibility of multi-site studies that aim to reliably assess subthreshold psychotic 
symptoms in individuals with 22q11.2DS. The pilot inter-site reliability obtained in 
this study encourage conducting international multi-site training and reliability. 
 Another limitation may relate to the cross-sectional rather than longitudinal 
nature of the current study design. As such, it was not possible to identify predictive 
factors of symptom progression over time. The predictive value of the SIPS in terms 
of the likelihood of those presenting with subthreshold symptoms to transition to 
psychosis constitutes an important topic with marked clinical implications, and studies 
that examine this question are currently underway.  
Moreover, there was no information on the age at onset or worsening of 
subthreshold psychotic symptoms in the current cohort, which undermines the ability 
to determine whether those with subthreshold symptoms qualify for clinical high risk 
or ultra-high risk status. In addition, since we used dual scoring for subthreshold 
psychotic symptoms measured by the SIPS and for psychiatric symptoms measured 
by the K-SADS the reported rates of negative/disorganized symptoms might have 
been inflated and the associations between subthreshold symptoms and higher rates of 
ADHD and lower FSIQ scores can therefore be biased. Nevertheless, at this early 
stage of applying the SIPS to individuals with a neurogenetic disorder, we ought to 
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adhere to the standard procedures. Prospective studies will need to examine these 
issues when adapting the SIPS to neurodevelopmental disorders considering relevant 
characteristics. Additionally, while the feasibility and utility of applying the SIPS to 
individuals with 22q11.2DS at various stages of development were supported by this 
study, there is still a need to standardize the methodology of its administration and 
verify its reliability in the context of 22q11.2DS subthreshold psychosis before it can 
be recommended for widespread clinical implementation. 
In conclusion, the present study indicates that nearly a third of 22q11.2DS 
individuals meet criteria for positive subthreshold psychotic symptoms and almost a 
quarter meet criteria for negative/disorganized subthreshold symptoms, with 
adolescents and young adults showing the highest rates of subthreshold symptoms. 
We found that 22q11.2DS individuals with subthreshold psychotic disorders have 
high rates of anxiety disorders and ADHD lower IQ and more impaired functioning. 
Future longitudinal studies would demonstrate the predictive value of 22q11.2DS 
subthreshold psychotic symptoms and its associated features in the context of the 
propensity to transition to psychosis. 
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Figure Legends: 
 
Figure 1. Comparison of the Mean Scores of Individual SIPS Items Between the Four 
22q11.2 Deletion Syndrome Age Groups;  
Mean+SEM; ** p<.01; *** p<.001. 
 
21 
 
References 
1.  Botto LD, May K, Fernhoff PM, et al. A Population-Based Study of the 
22q11.2 Deletion: Phenotype, Incidence, and Contribution to Major Birth 
Defects in the Population. Pediatrics. 2003;112(1):101-107. 
doi:10.1542/peds.112.1.101. 
2.  Schneider M, Debbané M, Bassett AS, et al. Psychiatric Disorders From 
Childhood to Adulthood in 22q11.2 Deletion Syndrome: Results From the 
International Consortium on Brain and Behavior in 22q11.2 Deletion 
Syndrome. Am J Psychiatry. 2014:1-13. doi:10.1176/appi.ajp.2013.13070864. 
3.  Green T, Gothelf D, Glaser B, et al. Psychiatric disorders and intellectual 
functioning throughout development in velocardiofacial (22q11.2 deletion) 
syndrome. J Am Acad Child Adolesc Psychiatry. 2009;48:1060-1068. 
doi:10.1097/CHI.0b013e3181b76683. 
4.  Morgan VA, Leonard H, Bourke J, Jablensky A. Intellectual disability co-
occurring with schizophrenia and other psychiatric illness: Population-based 
study. Br J Psychiatry. 2008;193(5):364-372. doi:10.1192/bjp.bp.107.044461. 
5.  Tang SX, Yi JJ, Moore TM, et al. Subthreshold psychotic symptoms in 
22q11.2 deletion syndrome. J Am Acad Child Adolesc Psychiatry. 2014;53(9). 
doi:10.1016/j.jaac.2014.05.009. 
6.  Bassett AS, Chow EWC. Schizophrenia and 22q11.2 deletion syndrome. Curr 
Psychiatry Rep. 2008;10(2):148-157. doi:10.1007/s11920-008-0026-1. 
7.  Gothelf D, Feinstein C, Thompson T, et al. Risk Factors for the Emergence of 
Psychotic Disorders in Adolescents with 22q11.2 Deletion Syndrome. The 
American journal of psychiatry 164, 663-669 (2007). 
doi:10.1176/appi.ajp.164.4.663. 
8.  Gothelf D, Schneider M, Green T, et al. Risk factors and the evolution of 
psychosis in 22q11.2 deletion syndrome: A longitudinal 2-site study. J Am 
Acad Child Adolesc Psychiatry. 2013;52(11). doi:10.1016/j.jaac.2013.08.008. 
9.  Stoddard J, Niendam T, Hendren R, Carter C, Simon TJ. Attenuated positive 
symptoms of psychosis in adolescents with chromosome 22q11.2 deletion 
syndrome. Schizophr Res. 2010;118(1-3):118-121. 
doi:10.1016/j.schres.2009.12.011. 
10.  Shapiro DI, Cubells JF, Ousley OY, Rockers K, Walker EF. Prodromal 
22 
 
symptoms in adolescents with 22q11.2 deletion syndrome and schizotypal 
personality disorder. Schizophr Res. 2011;129(1):20-28. 
doi:10.1016/j.schres.2011.03.030. 
11.  Schneider M, Van der Linden M, Glaser B, et al. Preliminary structure and 
predictive value of attenuated negative symptoms in 22q11.2 deletion 
syndrome. Psychiatry Res. 2012;196(2-3):277-284. 
doi:10.1016/j.psychres.2011.08.017. 
12.  Antshel KM, Shprintzen R, Fremont W, et al. Cognitive and Psychiatric 
Predictors to Psychosis in Velocardiofacial Syndrome: A 3-Year Follow-Up 
Study. J Am Acad Child Adolesc Psychiatry. 2010;49(4):333-344. 
doi:10.1097/00004583-201004000-00008. 
13.  Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the 
structured interview for prodromal syndromes and the scale of prodromal 
symptoms: predictive validity, interrater reliability, and training to reliability. 
Schizophr Bull. 2003;29(4):703-715. 
doi:10.1093/oxfordjournals.schbul.a007040. 
14.  Miller TJ, McGlashan TH, Rosen JL, et al. Prospective diagnosis of the initial 
prodrome for schizophrenia based on the structured interview for prodromal 
syndromes: Preliminary evidence of interrater reliability and predictive 
validity. Am J Psychiatry. 2002;159(5):863-865. 
doi:10.1176/appi.ajp.159.5.863. 
15.  Woods SW, Addington J, Cadenhead KS, et al. Validity of the prodromal risk 
syndrome for first psychosis: Findings from the north american prodrome 
longitudinal study. Schizophr Bull. 2009;35(5):894-908. 
doi:10.1093/schbul/sbp027. 
16.  Fusar-Poli P, Borgwardt S, Bechdolf A, et al. The psychosis high-risk state: a 
comprehensive state-of-the-art review. JAMA psychiatry. 2013;70(1):107-120. 
doi:10.1001/jamapsychiatry.2013.269. 
17.  Gothelf D, Eliez S, Thompson T, et al. COMT genotype predicts longitudinal 
cognitive decline and psychosis in 22q11.2 deletion syndrome. Nat Neurosci. 
2005;8(11):1500-1502. doi:10.1038/nn1572. 
18.  Vorstman JAS, Breetvelt EJ, Duijff SN, et al. Cognitive decline preceding the 
onset of psychosis in patients with 22q11.2 deletion syndrome. JAMA 
psychiatry. 2015;72(4):377-385. doi:10.1001/jamapsychiatry.2014.2671. 
23 
 
19.  Schneider M, Schaer M, Mutlu AK, et al. Clinical and cognitive risk factors for 
psychotic symptoms in 22q11.2 deletion syndrome: A transversal and 
longitudinal approach. Eur Child Adolesc Psychiatry. 2014;23(6):425-436. 
doi:10.1007/s00787-013-0469-8. 
20.  Gothelf D, Frisch A, Munitz H, et al. Clinical Characteristics of Schizophrenia 
Associated with Velo-Cardio-Facial Syndrome. Schizophrenia research 35, 
105-112 (1999). doi:10.1016/S0920-9964(98)00114-5. 
21.  Yi JJ, Calkins ME, Tang SX, et al. Impact of psychiatric comorbidity and 
cognitive deficit on function in 22q11.2 deletion syndrome. In: Journal of 
Clinical Psychiatry. Vol 76. ; 2015:e1262-e1270. doi:10.4088/JCP.14m09197. 
22.  Armando M, Girardi P, Vicari S, et al. Adolescents at ultra-high risk for 
psychosis with and without 22q11 deletion syndrome: A comparison of 
prodromal psychotic symptoms and general functioning. Schizophr Res. 
2012;139(1-3):151-156. doi:10.1016/j.schres.2012.04.020. 
23.  Rosen JL, Miller TJ, D’Andrea JT, McGlashan TH, Woods SW. Comorbid 
diagnoses in patients meeting criteria for the schizophrenia prodrome. 
Schizophr Res. 2006;85(1):124-131. doi:10.1016/j.schres.2006.03.034. 
24.  Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth 
at high clinical risk: a multisite longitudinal study in North America. Arch Gen 
Psychiatry. 2008;65(1):28-37. doi:10.1001/archgenpsychiatry.2007.3. 
25.  Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and 
Schizophrenia for School-Age Children-Present and Lifetime Version (K-
SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc 
Psychiatry. 1997;36(7):980-988. doi:10.1097/00004583-199707000-00021. 
26.  Reich W. Diagnostic interview for children and adolescents (DICA). J Am 
Acad Child Adolesc Psychiatry. 2000;39(1):59-66. doi:10.1097/00004583-
200001000-00017. 
27.  Angold  a, Prendergast M, Cox  a, Harrington R, Simonoff E, Rutter M. The 
Child and Adolescent Psychiatric Assessment (CAPA). Psychol Med. 
1995;25(4):739-753. doi:10.1017/S003329170003498X. 
28.  First MB et, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical 
Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV).; 1997. 
29.  Prosser H, Moss S, Costello H, Simpson N, Patel P, Rowe S. Reliability and 
validity of the Mini PAS-ADD for assessing psychiatric disorders in adults 
24 
 
with intellectual disability. J Intellect Disabil Res. 1998;42 ( Pt 
4)(August):264-272. 
30.  American Psychiatric Association. DSM-IV.; 2000. 
31.  Wechsler D. Wechsler Preschool and Primary Scale of Intelligence. 2002. 
doi:10.1007/978-1-4419-1698-3_866. 
32.  Wechsler D. Wechsler Intelligence Scale for Children-Revised (WISC-R).; 
1974. 
33.  Wechsler D. Wechsler intelligence scale for children–Third Edition. San 
Antonio, TX Psychol Corp. 1991. 
34.  McCrimmon  a. W, Smith  a. D. Review of the Wechsler Abbreviated Scale of 
Intelligence, Second Edition (WASI-II). J Psychoeduc Assess. 2012;31(3):337-
341. doi:10.1177/0734282912467756. 
35.  Wechsler D. WAIS‐ III Administration and Scoring Manual.; 1997. 
36.  Schimmelmann B, Michel C, Martz-Irngartinger A, Linder C, Schultze-Lutter 
F. Age matters in the prevalence and clinical significance of ultra-high-risk for 
psychosis symptoms and criteria in the general population: Findings from the 
BEAR and BEARS-kid studies. World Psychiatry. 2015;14(2):189-197. 
doi:10.1002/wps.20216. 
37.  Tang SX, Moore TM, Calkins ME, et al. The Psychosis Spectrum in 22q11.2 
Deletion Syndrome Is Comparable to That of Nondeleted Youths. Biol 
Psychiatry. 2016. doi:10.1016/j.biopsych.2016.08.034. 
38.  Fusar-Poli P, Carpenter WT, Woods SW, McGlashan TH. Attenuated 
psychosis syndrome: ready for DSM-5.1? Annu Rev Clin Psychol. 
2014;10(March):155-192. doi:10.1146/annurev-clinpsy-032813-153645. 
39.  Wigman JTW, van Nierop M, Vollebergh WAM, et al. Evidence that psychotic 
symptoms are prevalent in disorders of anxiety and depression, impacting on 
illness onset, risk, and severity--implications for diagnosis and ultra-high risk 
research. Schizophr Bull. 2012;38(2):247-257. doi:10.1093/schbul/sbr196. 
40.  Lin A, Wood SJ, Nelson B, Beavan A, McGorry P, Yung AR. Outcomes of 
Nontransitioned Cases in a Sample at Ultra-High Risk for Psychosis. Am J 
Psychiatry. 2015;172(3):249-258. doi:10.1176/appi.ajp.2014.13030418. 
41.  Schneider M, Armando M, Pontillo M, et al. Ultra high risk status and 
transition to psychosis in 22q11.2 deletion syndrome. World Psychiatry. 
2016;15(3):259-265. doi:10.1002/wps.20347. 
25 
 
42.  Swillen A, McDonald-Mcginn D. Developmental trajectories in 22q11.2 
deletion syndrome. Am J Med Genet Part C Semin Med Genet. 
2015;169(2):172-181. doi:10.1002/ajmg.c.31435. 
43.  Stephenson DD, Beaton EA, Weems CF, Angkustsiri K, Simon TJ. Identifying 
patterns of anxiety and depression in children with chromosome 22q11.2 
deletion syndrome: Comorbidity predicts behavioral difficulties and impaired 
functional communications. Behav Brain Res. 2015;276:190-198. 
doi:10.1016/j.bbr.2014.05.056. 
44.  Niarchou M, Martin J, Thapar A, Owen MJ, van den Bree MBM. The clinical 
presentation of attention deficit-hyperactivity disorder (ADHD) in children 
with 22q11.2 deletion syndrome. Am J Med Genet B Neuropsychiatr Genet. 
2015;168(8):730-738. doi:10.1002/ajmg.b.32378. 
45.  Piskulic D, Addington J, Cadenhead KS, et al. Negative symptoms in 
individuals at clinical high risk of psychosis. Psychiatry Res. 2012;196(2-
3):220-224. doi:10.1016/j.psychres.2012.02.018. 
46.  Gur RC, Calkins ME, Satterthwaite TD, et al. Neurocognitive growth charting 
in psychosis spectrum youths. JAMA Psychiatry. 2014;71(4):366-374. 
doi:10.1001/jamapsychiatry.2013.4190. 
47.  Schneider M, Van der Linden M, Menghetti S, Glaser B, Debbané M, Eliez S. 
Predominant negative symptoms in 22q11.2 deletion syndrome and their 
associations with cognitive functioning and functional outcome. J Psychiatr 
Res. 2014;48(1):86-93. doi:10.1016/j.jpsychires.2013.10.010. 
48.  Mekori-Domachevsky E, Guri Y, Yi J, et al. Negative subthreshold psychotic 
symptoms distinguish 22q11.2 deletion syndrome from other 
neurodevelopmental disorders: A two-site study. Schizophr Res. 2016. 
doi:10.1016/j.schres.2016.12.023. 
 
